137 related articles for article (PubMed ID: 6124330)
1. Renin in essential hypertension.
Atlas SA; Case DB
Clin Endocrinol Metab; 1981 Nov; 10(3):537-75. PubMed ID: 6124330
[No Abstract] [Full Text] [Related]
2. Why use angiotensin converting enzyme inhibitors to lower blood pressure?
MacGregor GA; Markandu ND; Smith SJ; Sagnella GA
J Cardiovasc Pharmacol; 1985; 7 Suppl 4():S92-7. PubMed ID: 2412021
[TBL] [Abstract][Full Text] [Related]
3. Inhibitors of the renin-angiotensin system. Effects on blood pressure, aldosterone secretion and renal function.
Atlas SA; Niarchos AP; Case DB
Am J Nephrol; 1983; 3(2-3):118-27. PubMed ID: 6191567
[No Abstract] [Full Text] [Related]
4. Captopril in the long-term treatment of essential hypertension: changes in the renin-angiotensin-aldosterone system.
Riegger GA; Steilner H; Hayduk K; Liebau G
Am J Cardiol; 1982 Apr; 49(6):1555-7. PubMed ID: 6803566
[TBL] [Abstract][Full Text] [Related]
5. Renin- and non-renin-mediated antihypertensive actions of converting enzyme inhibitors.
Zusman RM
Kidney Int; 1984 Jun; 25(6):969-83. PubMed ID: 6088887
[No Abstract] [Full Text] [Related]
6. Is angiotensin a prime factor in blood pressure control?
Am J Cardiol; 1982 Apr; 49(6):1434-9. PubMed ID: 6280476
[No Abstract] [Full Text] [Related]
7. [Renin-angiotensin system blocking drugs in the diagnosis and treatment of arterial hypertension].
Kabat M; Makowiecka-Cieśla M
Kardiol Pol; 1984; 27(2):147-57. PubMed ID: 6328092
[No Abstract] [Full Text] [Related]
8. Common genetic variations of the renin-angiotensin-aldosterone system and response to acute angiotensin I-converting enzyme inhibition in essential hypertension.
Hannila-Handelberg T; Kontula KK; Paukku K; Lehtonen JY; Virtamo J; Tikkanen I; Hiltunen TP
J Hypertens; 2010 Apr; 28(4):771-9. PubMed ID: 20027122
[TBL] [Abstract][Full Text] [Related]
9. Acute inhibition of the renin-angiotensin system: interest and limits to detect surgically curable hypertension.
Pagny JY; Thibonnier M; Corvol P; Menard J
J Cardiovasc Pharmacol; 1985; 7 Suppl 4():S82-5. PubMed ID: 2412019
[TBL] [Abstract][Full Text] [Related]
10. Participation of the renin system in treatment-resistant hypertension as measured by acute blockade of the angiotensin converting enzyme.
Weber MA; Drayer JI; Priest RT; Chen TC
Am J Nephrol; 1982; 2(1):6-11. PubMed ID: 6295161
[TBL] [Abstract][Full Text] [Related]
11. [Effect of inhibition of converting enzyme by captopril on arterial pressure, renin and aldosterone in essential hypertension].
Posadas C; Sánchez G; Boyer JL; Delmar M; Serrano PA
Arch Inst Cardiol Mex; 1982; 52(4):295-300. PubMed ID: 6291470
[TBL] [Abstract][Full Text] [Related]
12. Hormonal and metabolic effects of angiotensin converting enzyme inhibitors. Possible differences between enalapril and captopril.
Atlas SA; Case DB; Yu ZY; Laragh JH
Am J Med; 1984 Aug; 77(2A):13-7. PubMed ID: 6089554
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the hormonal and renal effects of captopril in severe essential and renovascular hypertension.
Aldigier JC; Plouin PF; Guyene TT; Thibonnier M; Corvol P; Menard J
Am J Cardiol; 1982 Apr; 49(6):1447-52. PubMed ID: 7041584
[No Abstract] [Full Text] [Related]
14. Effects of converting enzyme inhibition on blood pressure, plasma renin activity (PRA) and plasma aldosterone in hypertensive diabetics compared to patients with essential hypertension.
Sullivan PA; Kelleher M; Twomey M; Dineen M
J Hypertens; 1985 Aug; 3(4):359-63. PubMed ID: 2995484
[TBL] [Abstract][Full Text] [Related]
15. The effects of saralasin, an angiotensin II antagonist, on blood pressure and the renin-angiotensin-aldosterone system in normal and hypertensive subjects.
Brown JJ; Brown WC; Fraser R; Lever AF; Morton JJ; Robertson JI; Rosei EA; Trust PM
Aust N Z J Med; 1976 Aug; 6(3 Suppl):48-52. PubMed ID: 1071403
[TBL] [Abstract][Full Text] [Related]
16. [Saralasin-induced changes of blood pressure, renin and aldosterone in essential and renal hypertension (author's transl)].
Beyer J; Liebau G; Steiner B; Hayduk K
Klin Wochenschr; 1978 Sep; 56(17):859-64. PubMed ID: 713415
[TBL] [Abstract][Full Text] [Related]
17. Estimating renin participation in hypertension: superiority of converting enzyme inhibitor over saralasin.
Case DB; Wallace JM; Keim HJ; Weber MA; Drayer JI; White RP; Sealey JE; Laragh JH
Am J Med; 1976 Nov; 61(5):790-6. PubMed ID: 185903
[TBL] [Abstract][Full Text] [Related]
18. Captopril in clinical hypertension. Changes in components of renin-angiotensin system and in body composition in relation to fall in blood pressure with a note on measurement of angiotensin II during converting enzyme inhibition.
Atkinson AB; Morton JJ; Brown JJ; Davies DL; Fraser R; Kelly P; Leckie B; Lever AF; Robertson JI
Br Heart J; 1980 Sep; 44(3):290-6. PubMed ID: 7000102
[TBL] [Abstract][Full Text] [Related]
19. Blockade of the renin-angiotensin system.
Cheung BM
Hong Kong Med J; 2002 Jun; 8(3):185-91. PubMed ID: 12055364
[TBL] [Abstract][Full Text] [Related]
20. [Clinical experience with an oral angiotensin I-converting enzyme inhibitor in hypertensive patients: effects on blood pressure and the renin-aldosterone system by a single dose (author's transl)].
Mizuno K; Shigetomi S; Haruyama K; Matsui J; Gotho M; Fukuchi S
Nihon Jinzo Gakkai Shi; 1980 Jan; 22(1):1-11. PubMed ID: 6247526
[No Abstract] [Full Text] [Related]
[Next] [New Search]
